Asthma is a chronic inflammatory disease of the airways mediated, at least in part, by leukotrienes and other lipid mediators. Experimental studies have shown that lipid extract of the New Zealand greenlipped mussel (Perna canaliculus) is effective at inhibiting 59-lipoxygenase and cyclo-oxygenase pathways, which are responsible for the production of eicosanoids, including leukotrienes and prostaglandins [1] [2] [3] . The lipid extract Lyprinol is rich in eicosapentaenoic acid and docosahexanoic acid, v-3 fatty acids that inhibit the metabolism of arachidonic acid [4] . This extract is effective in reducing pain, swelling and stiffness and in improving the functional index in patients with rheumatoid arthritis and osteoarthritis [5, 6] . Its efficacy in thetreatment of airway inflammation is unknown.
The aim of this study is to assess the effect of lipid extract of New Zealand green-lipped mussel on symptoms, peak expiratory flow (PEF) and hydrogen peroxide (H 2 O 2 ) in expired breath condensate as a marker of airway inflammation in patients with atopic asthma in a double-blind randomised, placebocontrolled clinical trial.
Methods Patients
Volunteers aged 18-56 yrs with mild-to-moderate atopic asthma were recruited in the outpatients department of the Hospital Therapeutic Clinic, Pavlov Medical University, St.Petersburg, Russia (table 1) . Patients were diagnosed according to the American Thoracic Society definition of asthma [7] . Diagnosis was based upon clinical history, reversibility of forced expiratory volume in one second (FEV1) of w15% and diurnal variability of PEF of w20%. Atopic status was assessed by positive skinprick test (w3 mm) to common inhalant allergens (house-dust mite, animal allergens, pollen). All patients were sensitised to house-dust mite. Severity of asthma was classified according to the National Institutes of Health/World Health Organization (NIH/ WHO) guidelines [8] . Briefly, subjects with mild asthma had symptoms twice a week or less often with FEV1 o80% of predicted and used inhaled short-acting b 2 -agonists for symptom relief. Patients with moderate asthma had daily symptoms and an FEV1 between 60 and 80% pred, and used inhaled short-acting b 2 -agonists daily. Exclusion criteria were use of inhaled steroids within the previous 4 weeks, oral steroid treatment within the previous 3 months, current or exsmokers, clinically significant heart, renal, liver and intestinal disorders, women of childbearing potential not using adequate contraception. Only patients fully cooperative in all procedures were considered for inclusion in the run-in period of the trial.
The study was approved by the Local Ethics Committee and all participants gave written consent.
Study design
The study was a single-centre, double-blind, parallelgroup, randomised, placebo-controlled trial. Patients who fulfilled the inclusion criteria at the initial visit entered a 2 week observation run-in period, in which regular treatment was stopped and short-acting b 2 -agonists (salbutamol or terbutaline) as required were the only medications allowed. Asthma symptoms and use of rescue medications were recorded in a diary. Patients were excluded if they received inhaled steroids or were hospitalised for asthma during the run-in period.
After the run-in period patients were randomly assigned to receive either lipid extract of New Zealand green-lipped mussel, two capsules twice daily or matching placebo for a period of 8 weeks. Each lipid extract capsule contained 50 mg v-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and 100 mg olive oil (Lyprinol1, Mac Lab, Melbourne, Australia). Each identical placebo capsule contained 150 mg olive oil only. Randomisation was computer-generated in balanced blocks of two treatment regimens. Inhaled salbutamol delivered via pressurised metered-dose inhaler or terbutaline delivered by dry powder inhaler (Turbuhaler) were used as rescue medications throughout the study. No other medications were allowed. All short-acting inhaled b 2 -agonists were stopped at least 6 h before baseline FEV1 and exhaled H 2 O 2 measurements.
Measurements
Subjects kept a twice-daily dairy card throughout the study. They were provided with individual peakflow meters (Vitalograph Ltd, Buckingham, UK). The best of three peak flow values was recorded before taking the morning and evening study medications. Patients recorded daytime wheeze, nocturnal awakenings from asthma, daily use of short-acting inhaled b 2 -agonists and compliance with the study medications. Asthma symptoms were ranked on a scale from 0 (none) to 3 (very uncomfortable and interferes with normal activities). At the beginning and the end of the study, subjects attended the research clinic for measurement of FEV1, which was measured by dry spirometry (Vitalograph Ltd). The concentration of exhaled H 2 O 2 was measured at the beginning of the study, and at 4 and 8 weeks of treatment. Study medications and inhaled short-acting b 2 -agonists were withheld for at least 6 h before spirometry and exhaled H 2 O 2 measurements.
Expired breath condensate was collected using a glass condensing device, which was placed in a large chamber with ice as previously described [9] . After mouth rinsing, subjects breathed tidally through a mouthpiece for 20 min while wearing a nose-clip. The mouthpiece was also used as a saliva trap. The volume of condensate was 2-4 mL and H 2 O 2 was assayed immediately. H 2 O 2 was measured by using a colorimetric assay as described previously [10] . Briefly, 100 mL of condensate was mixed with 100 mL of 3,39,5,59 tetramethylbenzidine in 0.42 M citrate buffer, pH 3.8, and 10 mL of horseradish peroxidase (52.5 U?m -1 ). The samples were incubated at room temperature for 20 min and the reaction stopped by the addition of 10 mL 18 N sulphuric acid. The reaction product was measured spectrophotometrically (Model 46; Lomo Inc., St-Petersburg, Russia) at 450 nm. A standard curve of H 2 O 2 was performed for each assay.
Safety of the treatment
At each visit subjects were specially asked for any adverse events and health problems that may have occurred. All unusual signs and symptoms were recorded for further consideration. The safety of the treatment was evaluated by monitoring blood pressure, concentrations of creatinine, bilirubin, activity of liver transaminases and alkaline phosphatase in serum at clinical visits.
Analysis of data
Paired and unpaired two-tailed t-tests were used for statistical analysis. A p-value v0.05 was considered significant, and the data are expressed as mean ¡ SEM.
Results

Subjects
Of 60 volunteers recruited to the study, 46 fulfilled the entry criteria and were randomised to treatment. The most common reason for withdrawal before randomisation was deterioration in asthma control (14 subjects). These patients had a lower FEV1 (70.3 ¡ 2.1% pred) than those who were randomised (87.60¡2.5, pv0.001). All randomised patients completed the treatment and were included in the statistical analysis. Thirty six of them had mild asthma and 10 patients had moderate asthma.
Compliance
The mean self-recorded compliance with the twotimes daily study medications (Lyprinol or placebo) was 95% and 93%, respectively.
Asthma symptoms and bronchodilator use
Mean daytime wheeze was significantly reduced in patients treated with Lyprinol compared to those treated with placebo (table 2). There were no significant differences between the two treatment groups in respect to nocturnal awakening and use of short-acting b 2 -agonists (table 2) .
Lung function tests
Mean FEV1 and evening PEF during the treatment with Lyprinol did not significantly differ from those during the treatment with placebo. However, mean morning PEF was significantly higher during the treatment with Lyprinol than with placebo (table 2) . Data are expressed as mean¡SEM. D: change from baseline value; FEV1: forced expiratory volume in one second; PEF: peak expiratory flow; H 2 O 2 : hydrogen peroxide. Asthma symptoms were ranked on a scale from 0 (none) to 3 (very uncomfortable and interferes with normal activities).
Exhaled hydrogen peroxide
Safety of the treatment
One patient treated with Lyprinol and one patient treated with placebo had skin itch. One patient in the Lyprinol group and two patients in the placebo group complained of a metallic taste. There were no significant changes in blood pressure, or in concentrations of serum creatinine, bilirubin, liver transaminases or alkaline phosphatase in either group of patients (data not shown).
Discussion
The data from this study show that a stabilised lipid extract of New Zealand green-lipped mussel, Perna canaliculus (Lyprinol), reduces daytime wheeze and improves morning PEF in steroid-naïve patients with atopic asthma compared to placebo. There were no differences between patients treated with Lyprinol and placebo with respect to FEV1. It should be noted that most of the patients had mild asthma and FEV1w80% pred and thus there was little room for improvement in this measurement.
Lyprinol was well tolerated and had very few side-effects. The findings of the present study are in agreement with a previously published study [1] .
The mechanism by which lipid extract of New Zealand green-lipped mussels exerts its beneficial effect remains to be elucidated. Lyprinol inhibits leukotriene production by stimulated human polymorphonuclear leukocytes in vitro [2] . Much of this activity was associated with its content of v-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and antioxidants such as carotenoids. v-3 polyunsaturated acids inhibit arachidonate metabolism by 59-lipoxygenase and cyclo-oxygenase [6] , thus reducing the formation of leukotrienes and prostaglandins. Dietary supplementation with v-3 polyunsaturated fatty acids can suppress synthesis of interleukin-1 and tumour necrosis factor-a by mononuclear cells [11] . Epidemiological studies in Inuit, Dutch [12] , American [13] , Australian [14] and Japanese populations [15] have shown that a high dietary intake of v-3 polyunsaturated fatty acids is associated with lower incidence of cardiovascular disease and inflammatory diseases, such as asthma and rheumatoid arthritis. Dietary supplementation with fish oil rich in the v-3 polyunsaturated fatty acids over a 10-month period is beneficial in children with asthma following a strictly controlled diet and controlled allergen exposure [16] .
Leukotrienes are mediators of airway inflammation in asthma. They induce bronchoconstriction and airway smooth muscle proliferation [17, 18] , stimulate mucus secretion [19] , increase microvascular permeability and cause infiltration of inflammatory cells such as eosinophils and neutrophils into the airways [20, 21] . These cells release superoxide anions which then undergo spontaneous or enzyme-catalysed dismutation to form H 2 O 2 . H 2 O 2 is a highly reactive oxygen species involved in cellular injury via further reactions leading to hydroxyl radical and lipid peroxidation products [22] . Increased production of free radicals occurs in airway inflammation, and H 2 O 2 is detectable in exhaled air [23] .
Several studies have shown that H 2 O 2 in expired breath condensate may be a nondirect marker of oxidative stress and airway inflammation in asthmatic patients [24, 25] . Exhaled H 2 O 2 levels have previously been related to the eosinophil differential counts in induced sputum and activity of peripheral neutrophils in asthmatic patients [25, 26] . Therefore, elevated concentrations of H 2 O 2 may result from an enhanced number and activity of inflammatory cells in the airways.
In the present study, the authors found that elevated concentrations of exhaled H 2 O 2 were significantly decreased during treatment with Lyprinol compared to placebo. This may result from a reduction in the number of inflammatory cells in asthmatic airways because of decreased synthesis of leukotrienes and may also be due to the antioxidants such as b-carotene contained in Lyprinol.
In conclusion, this study shows that a lipid extract of New Zealand green-lipped mussel may have some beneficial effects in patients with steroid-naïve atopic asthma. Further clinical studies are needed to determine whether it may be useful as a supplement to other medications in the treatment of asthmatic patients.
